ProfileGDS5678 / 1420695_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 39% 36% 33% 39% 38% 37% 39% 39% 48% 39% 40% 58% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9027738
GSM967853U87-EV human glioblastoma xenograft - Control 22.9016739
GSM967854U87-EV human glioblastoma xenograft - Control 32.8126736
GSM967855U87-EV human glioblastoma xenograft - Control 42.7009933
GSM967856U87-EV human glioblastoma xenograft - Control 52.846639
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.944138
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9053437
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8885439
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8839939
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1155248
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.890539
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8854540
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4920458
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8903439